Performance Evaluation of Listed Pharmaceutical Companies Based on EVA

With the continuous growth of China's economy, the continuous improvement of people's living standards, the gradual improvement of the medical security system, and the increasingly prominent problem of aging population, China's pharmaceutical industry has shown a sustained good trend of development, maintaining a long-term output growth of more than 10%, becoming one of the fastest growing markets in the world. In this context, how to objectively evaluate the business performance of enterprises is a major problem facing pharmaceutical enterprises at present, and it is also the focus of investors and other stakeholders. This paper tries to introduce economic value added (EVA) index into the pharmaceutical industry, designs and adjusts the calculation formula of EVA, and takes HengRui Medicine as an example to make a specific analysis of its business performance, so as to provide reference for the performance evaluation of the pharmaceutical industry in China.